Trevi Therapeutics, Inc.

Trevi Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing Haduvio™ (oral nalbuphine ER) to treat chronic cough conditions. Their research focuses on targeting the central and peripheral nervous systems to alleviate cough. They are currently running clinical trials in patients with refractory chronic cough (RCC) and idiopathic pulmonary fibrosis (IPF), with topline data expected later in 2024. The company believes Haduvio has the potential to offer significant improvements to the quality of life for patients suffering from chronic cough, a condition that affects up to 10% of the adult population.

Trevi Therapeutics was founded in 2011 and is headquartered in New Haven, Connecticut. They are proud to be a part of the vibrant life-science community in the area. They are committed to the highest standards of scientific and pharmaceutical development and are dedicated to making a difference for patients with chronic cough for whom there are no approved treatment options. They have an 'all hands-on deck' approach and thrive in a fast-paced, entrepreneurial environment.

Trevi Therapeutics provides a comprehensive benefits package designed to support employee well-being and work-life balance. These benefits include comprehensive health coverage, generous contributions to a health savings account, life insurance, disability coverage, and paid time off. Family-friendly benefits include paid parental leave, paid sick time for family member care, and pet insurance. Competitive salaries, annual incentives, stock options, and a 401(k) with company match are also included.

Trevi Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing Haduvio™ (oral nalbuphine ER), an investigational therapy targeting chronic cough conditions. Their mission is to improve the lives of patients suffering from difficult-to-treat chronic cough, such as those with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), by providing a novel, dual-action approach that works both centrally and peripherally in the nervous system. Their research efforts are focused on developing safe and effective treatments for these debilitating conditions, for which there are currently no approved therapies.

Trevi Therapeutics fosters a fast-paced, entrepreneurial culture that emphasizes collaboration, innovation, and a commitment to improving patients' lives. The company values passionate and supportive team members who are dedicated to scientific excellence and pharmaceutical development. Trevi promotes a positive and collaborative work environment, encouraging employees to share their ideas and work together towards common goals. With a focus on building a strong team, Trevi embraces diversity and inclusivity, creating a welcoming and respectful workplace where everyone can contribute their unique skills and perspectives.